Compare PHAR & BHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAR | BHK |
|---|---|---|
| Founded | 1988 | 2001 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 668.8M |
| IPO Year | 2020 | N/A |
| Metric | PHAR | BHK |
|---|---|---|
| Price | $13.23 | $8.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $38.33 | N/A |
| AVG Volume (30 Days) | 10.1K | ★ 248.9K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.34% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | N/A | N/A |
| Revenue This Year | $10.04 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | $3,041.22 | ★ $8.81 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.54 | $8.94 |
| 52 Week High | $21.34 | $10.12 |
| Indicator | PHAR | BHK |
|---|---|---|
| Relative Strength Index (RSI) | 30.98 | 29.46 |
| Support Level | $11.83 | N/A |
| Resistance Level | $17.79 | $9.71 |
| Average True Range (ATR) | 0.42 | 0.06 |
| MACD | -0.34 | -0.02 |
| Stochastic Oscillator | 20.52 | 3.95 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing, under normal market conditions, at least 75% of its managed assets in bonds that are investment-grade quality at the time of investment. The trust, under a normal market scenario, will invest in a range of bonds, including corporate bonds, U.S. government and agency securities, and mortgage-related securities.